Bio-Techne 

$56.09
124
+$2.09+3.87% 今天

統計

當日最高
56.48
當日最低
54.65
52週高點
72.16
52週低點
43.2
成交量
257,165,622
平均成交量
-
市值
8.78B
本益比
77.14
股息殖利率
0.59%
股息
0.33

即將到來

股息

0.59%股息殖利率
May 26
$0.08
Feb 26
$0.08
Nov 25
$0.08
Aug 25
$0.08
May 25
$0.08
10年成長
不適用
5年成長
不適用
3年成長
不適用
1年成長
不適用

財報

11Aug預期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
下一步
0.39
0.44
0.5
0.56
預期EPS
0.531119
實際EPS
不適用

財務

6.02%利潤率
有盈利
2019
2020
2021
2022
2023
2024
2.44B營收
146.8M淨利

分析師評級

66.86平均目標價
最高預估為 80.00。
來自過去6個月內的 7 則評分。這不是投資建議。
買入
71%
持有
29%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 TECH 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.
Show more...
執行長
Mr. Kim Kelderman
員工
3100
國家
美國
ISIN
US09073M1045

上市

0 Comments

分享你的想法

FAQ

Bio-Techne 今天的股價是多少?
TECH 目前價格為 $56.09 USD,過去 24 小時上漲了 +3.87%。在圖表上更密切關注 Bio-Techne 股價表現。
Bio-Techne 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Bio-Techne 的股票以代號 TECH 進行交易。
Bio-Techne 的股價在上漲嗎?
TECH 股票較上週上漲 +6.36%,本月上漲 +29.33%,過去一年 Bio-Techne 上漲 +10.85%。
Bio-Techne 的市值是多少?
今天 Bio-Techne 的市值為 8.78B
Bio-Techne 下一次財報日期是什麼時候?
Bio-Techne 將於 August 11, 2026 公布下一次財報。
Bio-Techne 上一季度的財報如何?
TECH 上一季度的財報為每股 0.53 USD,預估為 0.53 USD,帶來 -0.79% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Bio-Techne 去年的營收是多少?
Bio-Techne 去年的營收為 2.44BUSD。
Bio-Techne 去年的淨利是多少?
TECH 去年的淨收益為 146.8MUSD。
Bio-Techne 會發放股息嗎?
是的,TECH 的股息每 每季 發放一次。每股最新股息為 0.08 USD。截至今日,股息殖利率(FWD)% 為 0.59%。
Bio-Techne 有多少名員工?
截至 June 15, 2026,公司共有 3,100 名員工。
Bio-Techne 位於哪個產業?
Bio-Techne從事於Health & Wellness產業。
Bio-Techne 何時完成拆股?
Bio-Techne 上次拆股發生於 November 30, 2022,比例為 4:1。
Bio-Techne 的總部在哪裡?
Bio-Techne 的總部位於 美國 的 Minneapolis。